Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Goserelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.62 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.55 |
| ▸ | APLNR | P35414 | 2/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Goserelin SCHEMBL16767395 | 1.00 | ABCC2 (0.64) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL22367929 | 1.00 | ABCC2 (0.64) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL14485644 | 1.00 | ABCC2 (0.64) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL5320254 | 1.00 | ABCC2 (0.64) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL25243029 | 0.99 | GNRHR (0.63) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL8643 | 0.99 | GNRHR (0.63) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL13660188 | 0.99 | GNRHR (0.63) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL29833872 | 0.99 | GNRHR (0.63) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL7544569 | 0.99 | GNRHR (0.63) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Goserelin SCHEMBL14193129 | 0.99 | GNRHR (0.63) | ABCC2GNRHRPTGS1C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 27022 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| EP-4694914-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| EP-4694915-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| US-6140315-A | Therapeutic uses of goserelin acetate | WEISMAN KENNETH M (US) | 2000-10-31 | — | — | US | claimed |
| US-6096764-A | ELIMINATING THE DETRIMENTAL SIDE-EFFECTS ASSOCIATED WITH THE CONTINUOUS AND CHRONIC USE OF GONDATROPIN-RELEASING HORMONE FACTOR OR AGONIST BY ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF BENZOTHIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | claimed |
| WO-2000040259-A1 | PROLONGED RELEASE MICROSPHERE ENCAPSULATING LUTEINIZING HORMONE-RELEASING HORMONE ANALOGUES AND METHOD FOR PREPARING THE SAME | DONG KOOK PHARMACEUTICAL CO., LTD. (KR) | 2000-07-13 | — | — | WO | claimed |
| WO-2000007599-A1 | PREVENTION OF ENDOMETRIOSIS SIGNS OR SYMPTOMS | HEINRICHS WILLIAM LEROY (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999008677-A1 | METHODS FOR INHIBITING DETRIMENTAL SIDE-EFFECTS DUE TO GnRH OR GnRH AGONIST ADMINISTRATION | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| EP-0897721-A2 | Benzo(b)thiophene derivatives for inhibiting detrimental side-effects due to GnRH or GnRH agonist administration | ELI LILLY AND COMPANY (US) | 1999-02-24 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0845265-A1 | MUCOSAL PREPARATION CONTAINING PHYSIOLOGICALLY ACTIVE PEPTIDE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-06-03 | — | — | EP | claimed |
| CN-1179723-A | Mucosal preparation containing physiologically active peptide | ASAHI CHEMICAL IND (JP) | 1998-04-22 | — | — | CN | claimed |
| WO-1998003183-A1 | USE OF 5,6-DIHYDRO-5-AZACYTIDINE IN THE TREATMENT OF PROSTATE CANCER | ILEX ONCOLOGY, INC. (US) | 1998-01-29 | — | — | WO | claimed |